{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Zinc Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_2",
        "name": "Tetrathiomolybdate Washout Period",
        "type": "Before",
        "unit": "years",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_3",
        "name": "Experimental Therapy Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening"
      },
      {
        "id": "timing_4",
        "name": "Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_5",
        "name": "Non-Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7
      },
      {
        "id": "timing_6",
        "name": "Alcohol Washout",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 48,
        "relativeTo": "First Dose",
        "windowLower": -48,
        "windowUpper": 0
      },
      {
        "id": "timing_7",
        "name": "End of Study Visit Window",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_8",
        "name": "Dose Titration Timing",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 29,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_9",
        "name": "SRC Safety Review Period",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 23,
        "relativeTo": "First Dose",
        "windowLower": 1,
        "windowUpper": 23
      },
      {
        "id": "timing_10",
        "name": "Outpatient Period Extension",
        "type": "After",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_11",
        "name": "Pregnancy Testing Frequency",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit"
      },
      {
        "id": "timing_12",
        "name": "Chelator Discontinuation",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "First Dose"
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "ALT/AST Elevation for Interruption",
        "instanceType": "Condition",
        "description": "Liver function test result triggering temporary dose interruption.",
        "text": "ALT or AST > 3x ULN and <= 5x ULN"
      },
      {
        "id": "cond_2",
        "name": "ALT/AST Elevation for Discontinuation",
        "instanceType": "Condition",
        "description": "Liver function test result triggering permanent dose discontinuation.",
        "text": "ALT or AST > 5x ULN"
      },
      {
        "id": "cond_3",
        "name": "Thrombocytopenia for Dose Reduction",
        "instanceType": "Condition",
        "description": "Platelet count triggering dose reduction.",
        "text": "Platelets < 100,000/mm3"
      },
      {
        "id": "cond_4",
        "name": "Neutropenia for Dose Reduction",
        "instanceType": "Condition",
        "description": "Neutrophil count triggering dose reduction.",
        "text": "Neutrophils < 1500/mm3"
      },
      {
        "id": "cond_5",
        "name": "Neutrophil Decrease for Dose Reduction",
        "instanceType": "Condition",
        "description": "Significant neutrophil decrease from baseline triggering dose reduction.",
        "text": "Neutrophils > 30% decrease from baseline and below reference range at baseline"
      },
      {
        "id": "cond_6",
        "name": "Hy's Law Condition",
        "instanceType": "Condition",
        "description": "Combination of bilirubin and ALT elevation indicative of liver injury, triggering temporary interruption.",
        "text": "Bilirubin > 2x ULN accompanied by ALT > 3x ULN"
      },
      {
        "id": "cond_7",
        "name": "Neurologic Worsening",
        "instanceType": "Condition",
        "description": "Evidence of neurologic worsening triggering evaluation for dose modification.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
      },
      {
        "id": "cond_8",
        "name": "Psychiatric Worsening",
        "instanceType": "Condition",
        "description": "Evidence of clinically significant acute psychiatric worsening triggering evaluation for dose modification.",
        "text": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis."
      },
      {
        "id": "cond_9",
        "name": "Pregnancy",
        "instanceType": "Condition",
        "description": "Confirmation of pregnancy is a criterion for study intervention discontinuation.",
        "text": "Participant becomes pregnant or plans to become pregnant."
      },
      {
        "id": "cond_10",
        "name": "Use of Disallowed Medication",
        "instanceType": "Condition",
        "description": "Use of disallowed medication is a criterion for study intervention discontinuation.",
        "text": "Participant uses a disallowed medication."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Dose Titration to 30 mg/day",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_30mg",
        "text": "On Day 29, participants will be administered ALXN1840 at 30 mg/day, following a safety review of data through Day 23. Participants may remain on 15 mg/day if there are safety concerns."
      },
      {
        "id": "trans_2",
        "name": "Dose Interruption for ALT/AST Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If ALT or AST > 3x ULN and <= 5x ULN, temporarily interrupt dosing. Requires weekly repeat testing."
      },
      {
        "id": "trans_3",
        "name": "Dose Discontinuation for ALT/AST Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If ALT or AST > 5x ULN, permanently discontinue study intervention."
      },
      {
        "id": "trans_4",
        "name": "Dose Reduction for Hematologic Toxicity",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Platelets < 100,000/mm3 OR Neutrophils < 1500/mm3 OR Neutrophils > 30% decrease from baseline, reduce dose to previous level or to 15 mg QOD. Requires weekly repeat testing."
      },
      {
        "id": "trans_5",
        "name": "Dose Interruption for Liver Injury",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Bilirubin > 2x ULN accompanied by ALT > 3x ULN, temporarily interrupt dosing. Requires weekly repeat testing."
      },
      {
        "id": "trans_6",
        "name": "Dose Modification for Neurologic/Psychiatric Worsening",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Investigator and Alexion Medical Monitor will evaluate the need for dose modification (interruption, increase or decrease) based on evidence of neurologic or psychiatric worsening."
      },
      {
        "id": "trans_7",
        "name": "Discontinuation of Study Intervention",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for: Serious hypersensitivity reaction; Severe uncontrolled infection; Use of disallowed medication; Pregnancy or planned pregnancy."
      },
      {
        "id": "trans_8",
        "name": "Rechallenge After Dose Modification",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "A maximum of 3 rechallenges will be allowed after dose interruption or reduction for safety events."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Participant Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_2",
        "name": "Investigator Discretionary Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_3",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities (EOS Visit on Day 54 +/- 2 days)."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered lost to follow-up if they repeatedly fail to return for visits and cannot be contacted after multiple attempts (3 phone calls and a certified letter)."
      },
      {
        "id": "exit_5",
        "name": "Sponsor/Investigator Termination of Study",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Alexion reserves the right to close the study site or terminate the study at any time. Reasons may include investigator non-compliance, inadequate recruitment, or discontinuation of study intervention development."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Titration Decision",
        "timepointId": "Day 29",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision to titrate dose from 15 mg/day to 30 mg/day based on review of safety data through Day 23 by the Safety Review Committee."
      },
      {
        "id": "dec_2",
        "name": "Ongoing Dose Modification Decision",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing decision points based on safety monitoring (lab results, AEs) that may trigger dose modification or discontinuation as per protocol criteria.",
        "conditionIds": [
          "cond_1",
          "cond_2",
          "cond_3",
          "cond_4",
          "cond_5",
          "cond_6",
          "cond_7",
          "cond_8"
        ]
      },
      {
        "id": "dec_3",
        "name": "Study Intervention Discontinuation Decision",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision to permanently discontinue a participant from the study intervention based on specific criteria such as severe lab abnormalities, pregnancy, or use of disallowed medications.",
        "conditionIds": [
          "cond_2",
          "cond_9",
          "cond_10"
        ]
      }
    ],
    "summary": {
      "timingCount": 12,
      "conditionCount": 10,
      "transitionRuleCount": 8,
      "exitCount": 5
    }
  }
}